Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: 7 US clinical trials tracked, none currently recruiting.
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition recurrent-ewing-sarcomaperipheral-primitive-neuroectodermal-tumor
OPEN 0 | RECR 0% | LATE 0 | EARLY 6 | RANK #2497 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor research.
National Cancer Institute (NCI) accounts for 6 of 7 trials (85.7%). 2 distinct sponsors appear on at least one study for this condition label.
-
Typical Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor enrolment sits around 100 participants.
Median target enrolment is 100 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03210714
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213652
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213704
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
Children's Oncology Group
NCT00048984
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT02304458
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00331643
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
NCT00030667
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor condition card totals 7 registered trials; most-linked intervention Bone Marrow Aspiration and Biopsy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.